133 related articles for article (PubMed ID: 37961024)
1. Changes in surgery rates among hospitalized patients with inflammatory bowel disease in Japan from 2015 to 2019: A nationwide administrative database analysis.
Yoshida S; Imai S; Fushimi K
J Gastroenterol Hepatol; 2024 Feb; 39(2):272-279. PubMed ID: 37961024
[TBL] [Abstract][Full Text] [Related]
2. Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy.
Lowe SC; Sauk JS; Limketkai BN; Kwaan MR
J Gastrointest Surg; 2021 Jan; 25(1):211-219. PubMed ID: 33140318
[TBL] [Abstract][Full Text] [Related]
3. Change in systemic steroid use and surgery rate in patients with inflammatory bowel disease: a Japanese real-world database analysis.
Hirayama D; Hyodo S; Morita K; Nakase H
J Gastroenterol; 2024 May; 59(5):389-401. PubMed ID: 38492011
[TBL] [Abstract][Full Text] [Related]
4. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study.
Khoudari G; Mansoor E; Click B; Alkhayyat M; Saleh MA; Sinh P; Katz J; Cooper GS; Regueiro M
Clin Gastroenterol Hepatol; 2022 May; 20(5):e974-e983. PubMed ID: 33065311
[TBL] [Abstract][Full Text] [Related]
5. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
[TBL] [Abstract][Full Text] [Related]
6. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Jung YS; Han M; Park S; Cheon JH
Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
Zhao M; Lirhus S; Lördal M; Langholz E; Knudsen T; Voutilainen M; Høivik ML; Moum B; Anisdahl K; Saebø B; Haiko P; Malmgren C; Coskun M; Melberg HO; Burisch J
Aliment Pharmacol Ther; 2022 Sep; 56(6):989-1006. PubMed ID: 35902223
[TBL] [Abstract][Full Text] [Related]
8. Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies.
Cai Q; Ding Z; Fu AZ; Patel AA
BMC Gastroenterol; 2022 Dec; 22(1):545. PubMed ID: 36581802
[TBL] [Abstract][Full Text] [Related]
9. Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study.
Seishima R; Okabayashi K; Ikeuchi H; Uchino M; Futami K; Noguchi T; Ohge H; Iseki Y; Watanabe K; Itabashi M; Okamoto K; Toiyama Y; Ogino T; Nakamura M; Yamada K; Wakai T; Sato Y; Kimura H; Takahashi K; Hida K; Kinugasa Y; Ishida F; Okuda J; Daito K; Koyama F; Ueno H; Yamamoto T; Yamamoto S; Hanai T; Maemoto A; Arakaki J; Komori K; Akagi Y; Shida D; Yamaguchi S; Matsuda K; Maeda K; Noake T; Nezu R; Sasaki S; Hasegawa J; Sunami E; Kanemitsu Y; Katsumata K; Uehara K; Kiyomatsu T; Suto T; Kazama S; Yamada T; Goi T; Ishihara S; Ajioka Y; Sugihara K
Am J Gastroenterol; 2023 Jul; 118(7):1248-1255. PubMed ID: 36622356
[TBL] [Abstract][Full Text] [Related]
10. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
Mao EJ; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 Jan; 45(1):3-13. PubMed ID: 27862107
[TBL] [Abstract][Full Text] [Related]
11. First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study.
Anisdahl K; Svatun Lirhus S; Medhus AW; Moum B; Melberg HO; Høivik ML
Scand J Gastroenterol; 2021 Oct; 56(10):1163-1168. PubMed ID: 34320885
[TBL] [Abstract][Full Text] [Related]
12. Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000.
Taida T; Ohta Y; Kato J; Ogasawara S; Ohyama Y; Mamiya Y; Nakazawa H; Horio R; Goto C; Takahashi S; Kurosugi A; Sonoda M; Shiratori W; Kaneko T; Yokoyama Y; Akizue N; Iino Y; Kumagai J; Ishigami H; Koseki H; Okimoto K; Saito K; Saito M; Matsumura T; Nakagawa T; Okabe S; Saito H; Kato K; Uehara H; Mizumoto H; Koma Y; Azemoto R; Ito K; Kamezaki H; Mandai Y; Masuya Y; Fukuda Y; Kitsukawa Y; Shimura H; Tsuyuguchi T; Kato N
Sci Rep; 2023 Aug; 13(1):13555. PubMed ID: 37604846
[TBL] [Abstract][Full Text] [Related]
13. Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases.
Han M; Jung YS; Cheon JH; Park S
J Gastroenterol Hepatol; 2019 Jul; 34(7):1166-1174. PubMed ID: 30672608
[TBL] [Abstract][Full Text] [Related]
14. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
[TBL] [Abstract][Full Text] [Related]
15. Postoperative Mortality After Nonelective Surgery for Inflammatory Bowel Disease Patients in the Era of Biologics.
Justiniano CF; Aquina CT; Becerra AZ; Xu Z; Boodry CI; Swanger AA; Monson JRT; Fleming FJ
Ann Surg; 2019 Apr; 269(4):686-691. PubMed ID: 29232213
[TBL] [Abstract][Full Text] [Related]
16. Early Initiation of Biologics and Disease Outcomes in Adults and Children With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort.
Lujan R; Buchuk R; Focht G; Yogev D; Greenfeld S; Ben-Tov A; Weisband YL; Lederman N; Matz E; Ben Horin S; Dotan I; Nevo D; Turner D
Gastroenterology; 2024 May; 166(5):815-825.e22. PubMed ID: 38331205
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Advanced Oral Small Molecules for Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
Solitano V; Vuyyuru SK; MacDonald JK; Zayadi A; Parker CE; Narula N; Peyrin-Biroulet L; Danese S; Feagan BG; Singh S; Ma C; Jairath V
J Crohns Colitis; 2023 Nov; 17(11):1800-1816. PubMed ID: 37317532
[TBL] [Abstract][Full Text] [Related]
18. Increased use of biologics in the era of TNF-α inhibitors did not reduce surgical rate but prolonged the time from diagnosis to first time intestinal resection among patients with Crohn's disease and ulcerative colitis - a Danish register-based study from 2003-2016.
Qvist N; Vadstrup K; Alulis S; Borsi A; Munkholm P; Olsen J
Scand J Gastroenterol; 2021 May; 56(5):537-544. PubMed ID: 33736551
[TBL] [Abstract][Full Text] [Related]
19. Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients.
Juliao-Baños F; Kock J; Arrubla M; Calixto O; Camargo J; Cruz L; Hurtado J; Clavijo A; Donado J; Schwartz S; Abreu MT; Damas OM
Medicine (Baltimore); 2021 Feb; 100(7):e24729. PubMed ID: 33607817
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
[No Abstract] [Full Text] [Related]
[Next] [New Search]
